-$0.20 Earnings Per Share Expected for Infinity Pharmaceuticals, Inc. (INFI) This Quarter
Brokerages expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to post ($0.20) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Infinity Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.21). Infinity Pharmaceuticals reported earnings per share of ($0.34) during the same quarter last year, which would suggest a positive year over year growth rate of 41.2%. The business is expected to announce its next quarterly earnings results on Thursday, August 2nd.
On average, analysts expect that Infinity Pharmaceuticals will report full-year earnings of ($0.74) per share for the current year, with EPS estimates ranging from ($0.77) to ($0.71). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.88) to ($0.59). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting the consensus estimate of ($0.18).
INFI traded up $0.01 on Friday, hitting $2.11. The company had a trading volume of 11,003 shares, compared to its average volume of 686,712. The firm has a market cap of $115.50 million, a P/E ratio of -2.54 and a beta of 2.50. Infinity Pharmaceuticals has a 1 year low of $2.11 and a 1 year high of $2.13.
In related news, major shareholder Value Fund L. P. Biotechnology acquired 1,510,000 shares of Infinity Pharmaceuticals stock in a transaction that occurred on Tuesday, April 10th. The shares were purchased at an average cost of $1.97 per share, for a total transaction of $2,974,700.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 11.45% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. BVF Inc. IL increased its stake in Infinity Pharmaceuticals by 24.2% during the fourth quarter. BVF Inc. IL now owns 9,766,508 shares of the biotechnology company’s stock worth $19,826,000 after purchasing an additional 1,900,400 shares during the period. Millennium Management LLC increased its stake in Infinity Pharmaceuticals by 105.3% during the fourth quarter. Millennium Management LLC now owns 1,198,854 shares of the biotechnology company’s stock worth $2,434,000 after purchasing an additional 614,806 shares during the period. Wasatch Advisors Inc. purchased a new stake in Infinity Pharmaceuticals during the first quarter worth about $747,000. Dimensional Fund Advisors LP increased its stake in Infinity Pharmaceuticals by 76.2% during the first quarter. Dimensional Fund Advisors LP now owns 734,272 shares of the biotechnology company’s stock worth $1,542,000 after purchasing an additional 317,583 shares during the period. Finally, GSA Capital Partners LLP increased its stake in Infinity Pharmaceuticals by 2,112.9% during the first quarter. GSA Capital Partners LLP now owns 302,154 shares of the biotechnology company’s stock worth $635,000 after purchasing an additional 288,500 shares during the period. Hedge funds and other institutional investors own 47.35% of the company’s stock.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.